ABERDEEN, Scotland and Singapore, 27th November 2017 – TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer’s disease, published online in the Journal of Alzheimer’s Disease.
Results from this study (TRx-237-005) are consistent with those from the first Phase 3 study, recently published in The Lancet [(TRx-237-015) Gauthier et al. 20161] in mild to moderate Alzheimer’s disease, in supporting the hypothesis that LMTX® might be effective as monotherapy at a dose as low as 4 mg twice daily.
Read more here.
Second Phase 3 Study Results for LMTX® published
TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX® in the Journal of Alzheimer’s Disease.
